Tumor urine samples | ||
Mean ± SD (range) | ||
Age (yr) | 67.5 ± 7.9 (45–85) | |
Gland weight (g)a | 48.21 ± 22.88 (16–180) | |
Serum PSA (ng/ml)b | 13.76 ± 36.1 (0.94–365) | |
Levels | N patients (%) | |
PSA (ng/ml)b | 0–4 | 6 (4) |
4–10 | 96 (65) | |
> 10 | 46 (31) | |
Gleason scorec | < 7 | 69 (46) |
≥ 7 | 81 (54) | |
Staged | T1 | 30 (27) |
T2 | 74 (65) | |
T3 | 8 (7) | |
T4 | 1 (1) | |
Treatment | RP | 69 (46) |
RT | 29 (19) | |
CRT | 23 (15) | |
AS | 23 (15) | |
HT | 7 (5) | |
Control urine samples | ||
Mean ± SD (range) | ||
Age (yr) | 67.2 ± 12 (21–97) | |
Serum PSA (ng/ml)e | 1.8 ± 1.06 (0.25–3.95) | |
N controls (%) | ||
BPH/Prostatitis | 35 (48) | |
LUTS | 18 (25) | |
Lithiasis | 5 (7) | |
Urethral stenosis | 4 (5) | |
Others | 11 (15) |